医学临床研究
  2025年5月7日 星期三           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (11): 1663-1666    DOI: 10.3969/j.issn.1671-7171.2023.11.014
  论著 本期目录 | 过刊浏览 | 高级检索 |
GnRH-a联合BREA治疗围绝经期异常子宫出血的临床疗效
雷晓娟, 李红艳, 郭天宝*
通用环球西安西航医院妇科,陕西 西安 710021
Clinical Efficacy of GnRH-a Combined with BREA in the Treatment of Perimenopausal Abnormal Uterine Bleeding
LEI Xiaojuan, LI Hongyan, GUO Tianbao
Department of Gynecology,Universal Global Xi'an Xihang Hospital,Xi'an Shaanxi 710021
全文: PDF (1238 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨促性腺激素释放激素激动剂(GnRH-a)联合双极射频子宫内膜去除术(BREA)治疗围绝经期异常子宫出血患者的疗效。【方法】选取2019年6月至2021年6月在本院诊治的86例围绝经期异常子宫出血患者,采用随机抽样法分为观察组和对照组,每组43例。对照组采用BREA治疗,观察组采用GnRH-a联合BREA治疗。比较两组有效率及治疗前后月经失血图(PBAC)评分、子宫体积、子宫内膜厚度、性激素[雌二醇(E2)、黄体生成素(LH)、卵泡刺激素(FSH)、孕酮(P)]水平。【结果】治疗前,两组PBAC评分比较,差异无统计学意义(P>0.05);治疗后3个月、6个月、12个月,两组PBAC评分均呈下降趋势,且观察组PBAC评分均低于对照组(P<0.05)。治疗后3个月、6个月、12个月,观察组有效率均高于对照组(P<0.05)。治疗前,两组E2、LH、FSH、P水平比较,差异无统计学意义(P>0.05);治疗后,两组E2、LH、FSH、P水平均降低,且观察组低于对照组(P<0.05)。治疗前,两组子宫体积和子宫内膜厚度比较,差异无统计学意义(P>0.05);治疗后6个月、12个月,两组子宫体积和子宫内膜厚度均减小,且观察组均小于对照组(P<0.05)。【结论】围绝经期异常子宫出血患者BREA治疗前采用GnRH-a进行预处理,可提高临床疗效,改善血清性激素水平,降低PBAC评分,具有临床推广价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
雷晓娟
李红艳
郭天宝
关键词 子宫出血/治疗围绝经期促性腺素释放激素/药理学子宫内膜消融技术    
Abstract:【Objective】To investigate the efficacy of gonadotropin-releasing hormone agonist(GnRH-a) combined with bipolar radiofrequency endometrial ablation(BREA) in the treatment of patients with perimenopausal abnormal uterine bleeding. 【Methods】From June 2019 to June 2021,86 patients with perimenopausal abnormal uterine bleeding treated in our hospital were selected and randomly divided into the observation group and the control group,with 43 cases in each group. The control group was treated with BREA,while the observation group received GnRH-a combined with BREA treatment. The efficacy rate,as well as changes in the Pictorial Blood Assessment Chart(PBAC) score,uterine volume,endometrial thickness,and levels of sex hormones [estradiol(E2),luteinizing hormone(LH),follicle-stimulating hormone(FSH),progesterone(P)] before and after treatment were compared between the two groups. 【Results】Before treatment,there was no significant difference in PBAC scores between the two groups(P>0.05). Three months,six months,and twelve months after treatment,PBAC scores of both groups showed a downward trend,and the PBAC scores of the observation group were consistently lower than those of the control group(P<0.05). The effective rate of the observation group was higher than that of the control group at three months,six months,and twelve months after treatment(P<0.05). Before treatment,there was no significant difference in the levels of E2,LH,FSH,and P between the two groups(P>0.05). After treatment,the levels of E2,LH,FSH,and P decreased in both groups,with the observation group showing lower levels than the control group(P<0.05). Before treatment,there was no significant difference in uterine volume and endometrial thickness between the two groups(P>0.05). Six months and twelve months after treatment,both uterine volume and endometrial thickness were reduced in both groups,with the observation group having smaller measurements than the control group(P<0.05). 【Conclusion】Pre-treatment with GnRH-a before BREA therapy in patients with perimenopausal abnormal uterine bleeding can improve clinical efficacy,adjust serum sex hormone levels,and reduce PBAC scores,and is of clinical value for widespread promotion.
Key wordsUterine Hemorrhage/TH    Perimenopause    Gonadotropin-Releasing Hormone/PD    Endometrial Ablation Techniques
收稿日期: 2023-02-16     
中图分类号:  R711.52  
通讯作者: * E-mail:15029961373@163.com   
引用本文:   
雷晓娟, 李红艳, 郭天宝. GnRH-a联合BREA治疗围绝经期异常子宫出血的临床疗效[J]. 医学临床研究, 2023, 40(11): 1663-1666.
LEI Xiaojuan, LI Hongyan, GUO Tianbao. Clinical Efficacy of GnRH-a Combined with BREA in the Treatment of Perimenopausal Abnormal Uterine Bleeding. JOURNAL OF CLINICAL RESEARCH, 2023, 40(11): 1663-1666.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.11.014     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I11/1663
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn